NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
02/16/2018
Back to search
Official data from USPTO
WUXI PHARMATECH
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Quick snapshot
WUXI PHARMATECH
ST13
US500000077188928Class
42
Filing
77188928
Registration
3444025
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
30
Latest update
02/16/2018
Classification
Registered
Trademark type
Word
Nice classes
42
Filing date
05/23/2007
Registration date
06/10/2008
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/16/2018
Last transaction
02/16/2018
Responsible office
United States Patent and Trademark Office
Status code
800
Official register
Principal Register
First use anywhere
2000-12-00
First use in commerce
2000-12-00
Drawing code
4
Owner type
16
Owner location
SHANGHAI, CN
Examiner
STIGLITZ, SUSAN R
Law office
L90
Current location
GENERIC WEB UPDATE
Holders and representatives
Holders
WUXI APPTEC CO., LTD.
WuXi PharmaTech Co., Ltd
Representatives
Colleen Flynn Goss FAY SHARPE LLP
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Pharmaceutical research and development; Scientific research and development; Consultation in the field of pharmaceutical research and development; Product research and development; Chemical laboratories; Chemical research; Chemical analysis; Mass spectrometry-based pharmacokinetics and pharmacodynamics (PK/PD) for drug metabolite profilingdrug metabolite identificationdrug metabolite quantitation; Mass spectrometry-based pharmacokinetics and pharmacodynamics (PK/PD) for biomarker profiling; Executing of chemical analyses; Scientific researchconducting clinical trials; Testing of pharmaceuticals
Publications
History of USPTO decisions and trademark events.
30 publications found
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
02/16/2018
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
02/16/2018
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
02/16/2018
E89R
TEAS SECTION 8 & 9 RECEIVED
01/26/2018
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
06/10/2017
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
06/25/2014
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
06/25/2014
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
06/25/2014
E815
TEAS SECTION 8 & 15 RECEIVED
06/10/2014
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
06/10/2014
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
06/10/2014
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
12/17/2008
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
09/04/2008
R.PR
REGISTERED-PRINCIPAL REGISTER
06/10/2008
PUBO
PUBLISHED FOR OPPOSITION
03/25/2008
NPUB
NOTICE OF PUBLICATION
03/05/2008
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
02/16/2008
ALIE
ASSIGNED TO LIE
02/16/2008
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/16/2008
XAEC
EXAMINER'S AMENDMENT ENTERED
01/16/2008
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
01/16/2008
GNEA
EXAMINERS AMENDMENT E-MAILED
01/16/2008
CNEA
EXAMINERS AMENDMENT -WRITTEN
01/16/2008
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/06/2007
GNRT
NON-FINAL ACTION E-MAILED
09/06/2007
CNRT
NON-FINAL ACTION WRITTEN
09/06/2007
DOCK
ASSIGNED TO EXAMINER
09/04/2007
MPMK
NOTICE OF PSEUDO MARK MAILED
05/31/2007
NWAP
NEW APPLICATION ENTERED
05/30/2007
Continuous trademark protection
Get notified about every new filing that threatens WUXI PHARMATECH or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.